Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.govpublic full text

Study to Demonstrate the Efficacy and Safety of Secukinumab up to 224 Weeks in Subjects With Active Peripheral Spondyloarthritis (pSpA).

Novartis Pharmaceuticals · 2022
ClinicalTrials.gov · Datasets · License: Public Domain · 2022
Open Source ↗
active peripheral spondyloarthritis (pspa), secukinumab, active peripheral spondyloarthritis (pspa), interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 800396
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.